HK inno.N's GERD drug K-CAB gets approval in Mexico

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegoprazan) has been approved by the Mexican Ministry of Health. This marks the first approval of the treatment in a Latin American country.

In Mexico, K-CAB has been approved for use in combination therapy with antibiotics for erosive and non-erosive gastroesophageal reflux disease, gastric ulcer and Helicobacter pylori eradication, under the brand name KI-CAB.

With this authorization, K-CAB was approved in four countries including Mexico, Singapore, Mongolia, and Indonesia. There are 26 countries in the process of reviewing or preparing for approval.

"With the approval in Mexico, K-CAB is set to promote Korean new drugs in Latin America." said Kwak Dalwon, CEO of HK inno.N. "We will further expand the range of the market to Europe and the Middle East so that it can become a global blockbuster drug."

Write to Ji-Hyun Lee at bluesky@hankyung.com